How GLP-1 Medications Work: From A Nutritionist’s Perspective
“How do GLP-1s work?” This is the question everyone wants to know – that and “should I start a GLP-1?” This article explores how GLP-1s work from a functional nutritionist’s perspective, highlights key factors to have in place to ensure successful outcomes, and explains how to navigate side effects.
What Does GLP-1 Stand For?
Glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1 medications, have rapidly transformed the landscape of metabolic health, diabetes care, and weight management.
What began as a treatment class designed to improve glycemic control in people with type 2 diabetes has evolved into one of the most powerful appetite-regulating and weight-loss interventions available in modern medicine. As their use expands, so does the confusion surrounding how they work, who they are appropriate for, and how to use them safely and sustainably—particularly from a nutritional standpoint.
GLP-1 Accessibility is Changing in 2026
At the same time, the regulatory environment surrounding GLP-1 medications is changing quickly. Access pathways that many individuals relied on over the past several years—including compounded formulations and micro-dosing strategies—are being eliminated. Beginning in 2026, GLP-1 medications will largely be restricted to FDA-approved prescription products, fundamentally changing how these drugs are used and managed.
As a functional medicine nutritionist who has both clinical experience with clients and personal experience using GLP-1s for my own diabetes management, I want to provide a comprehensive, evidence-informed overview of what these medications do, how the regulatory landscape is shifting, and why nutrition strategy is not optional when using them—especially at higher, fixed pharmaceutical doses.
How GLP-1 Medications Work in the Body
GLP-1 is a naturally occurring incretin hormone released from the gut in response to food intake. Its primary role is to coordinate digestion, insulin secretion, and appetite signaling. GLP-1 receptor agonists are synthetic compounds designed to mimic and amplify the physiological signal, thereby prolonging activation of GLP-1 receptors throughout the body.
How GLP-1 Receptor Agonists Work to Suppress Appetite and Improve Blood Sugar Regulation
When these receptors are stimulated, several key processes occur simultaneously:
- Insulin secretion increases in a glucose-dependent manner, meaning insulin is released more effectively when blood sugar levels are elevated.
- Glucagon secretion is suppressed, which reduces the amount of glucose released by the liver.
- Gastric emptying slows, which delays the movement of food from the stomach into the small intestine.
- Most notably, appetite and reward centers in the brain receive stronger satiety signals, leading to a significant reduction in hunger and food-seeking behavior.
This combination of effects explains why GLP-1 medications are so effective for both blood sugar regulation and weight loss. They are not simply appetite suppressants; they fundamentally alter how the brain and gut communicate around food intake.
GLP-1 Drug Names and How People Have Been Accessing Them
The most commonly prescribed GLP-1 receptor agonists include:
- Semaglutide
- Liraglutide (early GLP-1)
- Tirzepatide
- Retatrutide
Semaglutide (Ozempic, Wegovy) Explained
Semaglutide is marketed under the brand names Ozempic and Wegovy. It’s currently the most widely prescribed GLP-1 receptor agonist and has become the reference point for both diabetes management and medical weight loss.
Semaglutide’s long half-life allows for sustained receptor activation, resulting in pronounced appetite suppression, slower gastric emptying, and meaningful improvements in blood sugar control [1].
Because these effects are so strong, semaglutide often leads to rapid reductions in caloric intake, which can create nutritional risk if protein and total energy intake are not intentionally supported.
Tirzepatide (Mounjaro, Zepbound) and Dual GIP/GLP-1 Action
Tirzepatide, a newer compound that acts on both GLP-1 and GIP receptors, is sold under brand names like Mounjaro and Zepbound.
This GLP-1 differs from earlier generations like semaglutide in that it activates both GLP-1 and GIP receptors, amplifying its effects on appetite regulation, insulin sensitivity, and weight loss. This dual incretin action is one reason tirzepatide is associated with greater average weight loss in clinical trials, but it also increases the likelihood of profound appetite suppression [2].
As a result, individuals using tirzepatide often require even more deliberate nutrition planning to avoid excessive caloric restriction and lean body mass loss.
Retatrutide and the Next Generation of Multi-Agonist GLP Therapies
Retatrutide is a next-generation incretin-based therapy currently in phase 3 clinical trials and is not yet FDA-approved for clinical use, though it is circulating through experimental peptide suppliers.
Unlike semaglutide and tirzepitide, retatrutide acts on three receptors—GLP-1, GIP, and glucagon. Clinical trials have shown enhanced weight loss while also exerting anti-inflammatory and metabolic benefits beyond appetite suppression alone. While early trial data are promising, its potency underscores the growing need for structured nutritional oversight as these therapies become more widely available.
Pharmaceutical GLP-1s Are Only Available in Fixed Doses
Pharmaceutical versions of these drugs are produced as fixed-dose, single-use injection pens with standardized titration schedules. These products are expensive, often difficult to obtain, and designed to be prescribed at relatively high therapeutic doses based on large clinical trials conducted in populations with obesity or type 2 diabetes.
GLP-1 Compounding Pharmacies and Micro-Dosing Practices
In contrast, many individuals over the past several years have accessed GLP-1 medications through compounding pharmacies or peptide suppliers. Compounded formulations enabled customized dosing, including microdosing strategies that were not possible with commercial injection pens. Many people have used these lower doses for therapeutic purposes, such as:
- Appetite regulation,
- Blood sugar stabilization,
- Metabolic support
- Longevity optimization
Rather than aggressive clinical weight loss, the results have been profound for many, though not without side effects.
Peptide-Based GLP-1s Sold as Research Compounds
GLP-1 analogs have also been available for a long time from peptide suppliers that sell compounds labeled “research use only.” While these products were not FDA-approved for human use, they became a common access point for individuals seeking more flexible dosing options outside of traditional prescription models.
With the changing landscape and the more accessible, affordable options going away in 2026, nutritional guidance around GLP-1s (both at high pharmaceutical doses and for those coming off microdoses due to loss of accessibility) matters now more than ever!
Regulatory Changes: Why This Is All About to Change
Why Compounded GLP-1 Medications Are Being Restricted
The FDA has significantly increased enforcement around compounded GLP-1 products. As of recent regulatory updates, compounded versions of semaglutide and tirzepatide are no longer broadly permitted unless specific legal criteria are met, such as documented clinical necessity when commercial products cannot meet an individual patient’s needs. Large-scale compounding of GLP-1s that directly copy FDA-approved drugs is no longer allowed.
Peptide suppliers marketing GLP-1 analogs as research compounds are also under increased scrutiny. These products are not FDA-approved for human use, and access through these channels is expected to become increasingly restricted.
What the FDA’s Position Means for Micro-Dosing GLP-1s
Beginning in 2026, most individuals will only be able to access GLP-1 medications through FDA-approved pharmaceutical products prescribed by licensed providers. This shift has major implications:
- Micro-dosing strategies will be far more difficult to implement
- Dosing flexibility will be limited
- Costs will remain high
- Off-label use may become more complicated to justify and maintain.
Will Pharmaceutical Companies Offer Lower-Dose GLP-1 Options?
At present, there is no clear indication that pharmaceutical companies plan to release widely available lower-dose or microdose versions of these medications. While titration schedules exist, they are designed to lead patients toward relatively high maintenance doses rather than long-term low-dose use.
Why Nutrition Counseling Becomes Even More Critical at Pharmaceutical Doses
How GLP-1s work on Appetite Suppression Leads to Unintentional Undereating
One of the most overlooked aspects of GLP-1 therapy is the profound impact these drugs have on energy intake. Appetite suppression is not subtle. Many individuals report needing to consciously remind themselves to eat.
While this may seem beneficial in the context of weight loss, it carries significant nutritional risks if not managed carefully [3].
The Risk of Lean Body Mass Loss on GLP-1 Drugs
When caloric intake drops rapidly and unintentionally, protein intake often falls below physiologically adequate levels. This creates a high risk of lean body mass loss. Muscle tissue is metabolically protective; losing it can:
- Worsens insulin sensitivity [4]
- Reduce resting metabolic rate [5]
- Increase long-term cardiometabolic risk [6]
- Shortened lifespan [7]
Micronutrient Deficiencies Seen in GLP-1 Users
Micronutrient deficiencies can also develop when overall food volume decreases. Iron, B vitamins, magnesium, zinc, and fat-soluble vitamins are particularly vulnerable when dietary intake becomes inconsistent or overly restrictive [8].
This is not theoretical. Clinical data and real-world experience consistently show that individuals on GLP-1 medications who do not receive nutritional guidance lose both fat mass and lean mass. Over time, this can leave them metabolically worse off despite a lower number on the scale [8, 9].
Protein Intake and Lean Mass Preservation
Protein intake is the single most important nutritional variable to address while using GLP-1 medications. Adequate protein helps preserve muscle mass, supports satiety, stabilizes blood sugar, and mitigates some of the metabolic slowdown associated with rapid weight loss [10].
How do GLP-1s work on protein intake? In practice, many individuals on GLP-1s struggle to meet protein needs because appetite suppression makes high-protein foods less appealing or difficult to consume in sufficient quantities. This is where structured planning becomes essential rather than optional.
Without a clear strategy, people often default to eating small portions of whatever feels easiest to tolerate, which is often low in protein and nutrients. Over time, this pattern contributes to:
- Muscle loss
- Fatigue
- Hair thinning
- Impaired metabolic resilience.
How GLP-1s Work: Side Effects of GLP-1s
As with any medication, GLP-1s like semaglutide and tirzepitide are not without side effects. They affect everyone differently, with some experiencing significant side effects and others noticing only appetite suppression. It’s important to work with a qualified healthcare provider to help navigate these concerns and to support the body with essential nutritional support.
How GLP-1s Work: Mood Changes, Dopamine, and Depression Risk
How GLP-1s Work: Influence on Dopamine and Reward Pathways
GLP-1 receptors are present not only in the gut but also in the brain, including regions involved in reward processing and dopamine signaling. This explains how GLP-1 influences addictive behaviors and compulsive patterns related to food, alcohol, smoking, gambling, and other dopamine-driven behaviors [11].
For many individuals with obesity or addiction-related patterns, this effect can be profoundly beneficial. Reduced reward-seeking can support behavior change and long-term health improvements.
How GLP-1s Work: Depression and Emotional Blunting on GLP-1 Medications
However, in lean individuals or those using GLP-1s primarily for glycemic control or mild appetite regulation, this same mechanism can lead to emotional blunting or depressive symptoms. This is something I personally experienced after several months of continuous use. Reduced dopamine signaling can alter emotional reward, motivation, and overall mood [12].
This effect is not universally discussed in prescribing settings, yet it is clinically relevant—particularly for individuals who are not using GLP-1s for obesity treatment. I’ve personally experienced this effect in use for diabetes management (with strict dietary compliance underneath), and I’ve heard from several other individuals who’ve experienced the same effect.
How GLP-1s Work: Cycling Strategies and Personal Experience
In my own experience managing type 1 diabetes, I have found that cycling GLP-1 use—typically six to eight weeks on followed by six to eight weeks off—helps mitigate mood changes. While the glycemic benefits are not preserved during the off-cycle, appetite management (aka, my tendency to snack and graze) is for several weeks.
This approach is not appropriate for everyone and should always be discussed with a qualified medical provider. Still, it highlights the importance of individualized use rather than one-size-fits-all dosing.
As access becomes more restricted and pharmaceutical dosing becomes the norm, these nuanced strategies may become harder to implement, further emphasizing the need for professional guidance.
How GLPs Work to Influence Gastrointestinal Side Effects and Gastroparesis Risk
Slowed gastric emptying is a core mechanism of action of GLP-1 medications. While this contributes to satiety and blood sugar stability, it can also cause significant gastrointestinal side effects. Nausea, bloating, constipation, and reflux are common, particularly during dose escalation [13].
In some cases, prolonged or excessive slowing of gastric emptying can contribute to gastroparesis. This is counterproductive to metabolic health and can severely impair quality of life if not addressed early [14].
Nutritional strategies—including meal composition, texture modification, fiber timing, and fat distribution—play a critical role in minimizing these side effects.
Coming Off GLP-1 Medications: What to Expect
Discontinuation of GLP-1 therapy often leads to a rebound in appetite signals. Hunger increases, food preoccupation may return, and weight regain is common if no behavioral or nutritional framework is in place [15].
For some individuals, GLP-1 use serves as a window to reset eating behaviors and metabolic patterns. For others, the effects are temporary, and discontinuation can feel destabilizing both physically and emotionally.
This variability underscores the importance of preparing for both use and discontinuation rather than viewing GLP-1s as a permanent solution without supportive infrastructure.
Why Coaching and Nutrition Support Matter
One of the most concerning trends surrounding GLP-1 medications is how frequently they are prescribed without any dietary counseling. Many individuals receive a prescription from a physician or weight-loss clinic with little to no guidance on protein intake, caloric adequacy, micronutrient support, or long-term strategy.
Without this support, people are at risk for muscle loss, nutrient deficiencies, mood disturbances, and poor long-term outcomes. GLP-1 medications are powerful tools, but they require equally powerful nutritional frameworks to be used safely.
Final Thoughts
GLP-1 medications are among the most effective metabolic interventions we currently have. They can dramatically improve blood sugar control, support meaningful weight loss, and reduce addictive behaviors. At the same time, they are not benign. They profoundly alter appetite, reward pathways, digestion, and nutrient intake.
As regulatory changes limit access to flexible dosing and compounded options, understanding how to eat appropriately while using these medications becomes even more critical. Nutrition is not an afterthought—it is the foundation that determines whether GLP-1 therapy supports long-term health or undermines it.
Work With Me to Get This Right
If you are using—or considering using—a GLP-1 medication, you should not be navigating this alone. I work with clients to develop individualized nutrition strategies that preserve lean mass, support metabolic health, manage side effects, and create sustainable outcomes both on and off medication.
Want to learn more about how GLP-1s work, or are you interested in using GLP-1s intelligently, safely, and with your long-term health in mind? I invite you to work with me directly. Together, we’ll build a plan that supports your physiology—not just the scale.
Book a free discovery call to set yourself up for long-term success with GLP-1s going into 2026.
